AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$BBNX

Mensinger Mike sold $84K of BBNX

Mensinger Mike (Chief Product Officer) sold 4,375 shares of Beta Bionics, Inc. (BBNX) at $19.11 on 2026-09-02.

Original reporting
SEC EDGAR · Mensinger Mike
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBNX
Bearish
medium confidence
Mentioned
$BBNX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBNXBearishLow
01

Why it matters

Provides fresh data on insider holdings; useful for compliance and sentiment monitoring.

02

Market read

Minor insider sale with limited trading impact.

03

What to watch

Holding remains sizable; sale could be routine liquidity need.

Relevance 3/10Novelty 4/10Timing: post-market 2026-09-03

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$BBNXBearishMedium confidence
Context

Chief Product Officer sold 4,375 shares for $83,620, reducing his stake to 180,040 shares.

Expected impact

minor downward pressure or flat price action

Evidence & confidence

Sale size is modest relative to market cap; insider remains a large holder, so impact is limited.

Market effects

Sector

No broader sector impact; biotech sector unchanged.

Regional

Limited to US biotech investors.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not indicate company weakness.

Key entities

  • Company
    Beta Bionics, Inc.

    Medical device company listed on Nasdaq under BBNX.

  • Insider
    Mensinger Mike

    Chief Product Officer of Beta Bionics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBNX insider trading history →

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min